StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX)

Equities research analysts at StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a report issued on Monday. The firm set a “sell” rating on the stock.

A number of other research firms have also weighed in on VNRX. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd. D. Boral Capital restated a “buy” rating and set a $5.00 price target on shares of VolitionRx in a research report on Tuesday, December 10th.

VolitionRx Stock Down 0.8 %

Shares of VNRX opened at $0.62 on Monday. VolitionRx has a twelve month low of $0.43 and a twelve month high of $1.23. The stock has a market cap of $56.99 million, a PE ratio of -1.71 and a beta of 1.17. The business’s 50-day moving average price is $0.66 and its 200-day moving average price is $0.66.

Insider Transactions at VolitionRx

In other news, Director Guy Archibald Innes bought 174,764 shares of VolitionRx stock in a transaction that occurred on Monday, December 9th. The shares were acquired at an average price of $0.57 per share, with a total value of $99,615.48. Following the completion of the purchase, the director now directly owns 617,085 shares in the company, valued at $351,738.45. The trade was a 39.51 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Cameron John Reynolds purchased 139,811 shares of the stock in a transaction on Monday, December 9th. The shares were purchased at an average price of $0.57 per share, for a total transaction of $79,692.27. Following the transaction, the chief executive officer now directly owns 2,117,404 shares of the company’s stock, valued at approximately $1,206,920.28. This represents a 7.07 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 358,266 shares of company stock valued at $204,212. 12.80% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC lifted its holdings in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 45,959 shares of the company’s stock after purchasing an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 8.09% of the company’s stock.

VolitionRx Company Profile

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.